199 results on '"Pistelli, Mirco"'
Search Results
2. A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
3. A Mixed-apprOach program To help women wIth breast cancer stay actiVE (MOTIVE program): A pilot-controlled study
4. Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO)
5. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients
6. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
7. Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review
8. Adjuvant Systemic Therapy in DCIS
9. Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype
10. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
11. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
12. Correction to: Expectations and psychological issues before genetic counseling: analysis of distress determinant factors
13. Expectations and psychological issues before genetic counseling: analysis of distress determinant factors
14. Role of DCE-MR in predicting breast cancer subtypes
15. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials
16. Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review
17. Adjuvant Systemic Therapy in DCIS
18. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma
19. Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
20. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients
21. Phase Angle Research Study in NeoplastIc Patients Treated with Standard Chemotherapy (PARSNIP)
22. The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience
23. Role of maspin in cancer
24. Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
25. sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
26. Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy
27. Abstract PD11-03: Assessing the impact of 12 months lifestyle interventions on breast cancer secondary prevention: A modeling approach
28. Additional file 2 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
29. Additional file 1 of EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
30. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
31. A Mixed-Appr Oach Program To Help Women W Ith Breast Cancer Stay Acti VE ( MOTIVE Program): A Pilot-Controlled Study
32. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
33. Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice
34. Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO)
35. EFFECT: A randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
36. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence
37. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
38. Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)
39. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting
40. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience
41. Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
42. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
43. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
44. Long‑responders to anti‑HER2 therapies: A�case�report and review of the literature
45. Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035)
46. The importance of obstetric(midwife) in breast cancer prevention and recurrence.
47. Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy
48. Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?
49. Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes
50. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.